Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TL011
TL011, anti CD20, for the treatment of rheumatoid arthritis · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| TL011 | EXPERIMENTAL | - |
| MabThera® | ACTIVE_COMPARATOR | - |
| MabThera | ACTIVE_COMPARATOR | MabThera infusions |
| Name | Type | Description |
|---|---|---|
| TL011 | BIOLOGICAL | 375 mg/m2 iv every 3 weeks for 8 cycles |
| Rituximab | BIOLOGICAL | 375 mg/m2 iv every 3 weeks for 8 cycles |
| TL011, anti CD20, for the treatment of rheumatoid arthritis | BIOLOGICAL | TL011 administered by 2 infusions, 2 weeks apart |
| MabThera infusions | BIOLOGICAL | MabThera, administered by 2 infusions, 2 weeks apart |
Inclusion Criteria: * Newly diagnosed subjects with a confirmed pathologic diagnosis of diffuse large B cell non-Hodgkin's lymphoma (DLBCL) based on the 2008 World Health Organization classification. 2.CD20+ lymphoma cells at screening * 18-80 (inclusive) years of age at screening * Ann Arbor St...
Top 20 of 26 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Adalimumab, Upadacitinib, Lutikizumab, Ravagalimab |
| Bristol-Myers Squibb Company | BMY | 6 | PHASE3 | Abatacept, Zolacabtagene autoleucel, BMS-986528, BMS-986454 |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Baricitinib, LY4213663, LY4298445 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Guselkumab |
| AstraZeneca PLC | AZN | 4 | PHASE2 | AZD1163, AZD0120, AZD5492, Surovatamig |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | Ianalumab, PIT565, Secukinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Tulisokibart, MK-1045 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Sarilumab, SAR448501 |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| XBiotech, Inc. | XBIT | 1 | PHASE2 | Natrunix |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE2 | AB-101 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | GS-0151 |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | Plamotamab |
| Adicet Bio Inc | ACET | 1 | PHASE1 | ADI-001 |
| Pfizer Inc. | PFE | 2 | - | tofacitinib |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE1 | JADE201 |
TL011 is an investigational monoclonal antibody developed by Teva Pharmaceutical Industries Limited (ticker: TEVA). It has been studied in Phase 1 clinical trials for CD20-positive diffuse large B cell lymphoma (DLBCL) and for severe, active rheumatoid arthritis. It is not an approved therapy and remains in clinical development.
TL011 was studied as a treatment for severe, active rheumatoid arthritis in adults 18 years and older. That Phase 1 trial, NCT01123070, was completed and enrolled 54 participants across Czechia, Hungary, Italy, Spain, and the United Kingdom. TL011 is investigational and has not been approved for rheumatoid arthritis.
TL011 is an anti-CD20 monoclonal antibody, meaning it targets the CD20 protein found on B cells. This target class underlies its investigation in B cell lymphoma and in rheumatoid arthritis, where B cells contribute to disease activity. TL011 is a monoclonal antibody modality asset.
TL011 is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva sponsored the Phase 1 studies of TL011 in CD20-positive diffuse large B cell lymphoma and in severe, active rheumatoid arthritis.
TL011 is in Phase 1 development. Both of its recorded trials were Phase 1 studies and both are completed, with no active trials currently listed. TL011 is investigational and has not been approved by the FDA for any indication.
TL011 has been evaluated in two completed Phase 1 trials. NCT01205737 was a double-blind, randomized, active-controlled study in CD20-positive diffuse B cell non-Hodgkin's lymphoma, enrolling 186 participants. NCT01123070 studied TL011 in severe, active rheumatoid arthritis and enrolled 54 participants.